Shots:
- Verily has expedite the COVID-19 testing with a new lab-based at South San Francisco. The lab will use the technology from Thermo Fisher Scientific’s TaqPath test kit that has received the US FDA’s EUA to test COVID-19
- Verily has submitted a EUA for an adaptation of the TaqPath test to use in testing pooled patient specimens. Pooling is expected to enable our clinical lab to increase our testing capacity even further while maintaining a high level of overall test performance.
- Additionally, the company has verified the Roche Elecsys anti-SARS-CoV-2 Ab test and plans to implement additional tests in our lab
Click here to read full press release/ article | Ref: Verily | Image: The Business Journal
